ACA
CADL icon

Acorn Capital Advisors’s Candel Therapeutics CADL Stock Holding History

Acorn Capital Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.2M Buy
3,497,948
+917,431
+36% +$4.99M 4.89% 6
2025
Q4 		$14.6M Hold
2,580,517
– – 4.94% 6
2025
Q3 		$13.2M Hold
2,580,517
– – 6.68% 6
2025
Q2 		$13.1M Buy
2,580,517
+428,265
+20% +$2.2M 8.54% 5
2025
Q1 		$12.2M Buy
2,152,252
+212,608
+11% +$1.74M 8.11% 5
2024
Q4 		$16.8M Buy
+1,939,644
New +$11.5M 9.06% 3

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return

Acorn Capital Advisors's CADL Position: Q1 2026 in Review

Acorn Capital Advisors increased its Candel Therapeutics (CADL) stake by 36% in Q1 2026, buying an estimated $4.99M and bringing the position to 3,497,948 shares worth $17.2M. The position accounts for 4.89% of the portfolio, ranked #6.

Acorn Capital Advisors first reported a position in CADL in Q4 2024 and has held it in 6 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Acorn Capital Advisors held 3,497,948 shares of Candel Therapeutics worth $17.2M as of Q1 2026.
  • Acorn Capital Advisors bought 917,431 Candel Therapeutics shares in Q1 2026, an estimated $4.99M.
  • Candel Therapeutics made up 4.89% of Acorn Capital Advisors's portfolio in Q1 2026, its #6 holding.
  • Acorn Capital Advisors first reported a position in Candel Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.